Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients: A Real-World Study

BACKGROUND: Ustekinumab, as a monoclonal antibody against interleukin (IL)-12 and IL-23, gets approved in China since 2019, therefore fewstudies report the application of ustekinumab in treating Chinese psoriasis patients in the real clinical settings until now. AIMS: Thus, this study aimed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xue, Qin, Guifang, Meng, Zudong, Pei, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751685/
https://www.ncbi.nlm.nih.gov/pubmed/35068529
http://dx.doi.org/10.4103/ijd.IJD_232_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751685/
https://www.ncbi.nlm.nih.gov/pubmed/35068529
http://dx.doi.org/10.4103/ijd.IJD_232_21

Ejemplares similares